Malignancy After Solid Organ Transplantation: An Overview

Zafar, S. Yousuf; Howell, David N.; Gockerman, Jon P.

doi:10.1634/theoncologist.2007-0251

Cited by 82 publications

(68 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13,14 Gastrointestinal, genitourinary, lung, and oropharyngeal tumors also may develop after liver transplant. In the present study, there were no skin, lung, or oropharyngeal cancers.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Sanaei

Aliakbarian²,

Kazemi³

et al. 2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Patients who have liver transplant are at high risk of developing de novo malignancies. The purpose of this study was to evaluate incidence and histologic type of de novo malignancies after liver transplant in a liver transplant center. Materials and Methods: In 1700 patients who had orthotopic liver transplant from deceased and living donors from January 1992 to October 2012, de novo malignancies after transplant were analyzed. Results: There were 38 patients (2.2%) who developed de novo malignancy. Pathologic diagnosis was posttransplant lymphoproliferative disorder in 24 patients (63%), gastrointestinal adenocarcinoma in 4 patients (10%), Kaposi sarcoma in 3 patients (8%), pancreatic head adenocarcinoma in 2 patients (5%), papillary thyroid carcinoma in 1 patient (3%), lumbosacral multiple myeloma in 1 patient (3%), conjunctive carcinoma in 1 patient (3%), testicular cancer in 1 patient (3%), and metastatic adenocarcinoma to the vertebrae of unknown origin in 1 patient (3%). In the 24 patients who had posttransplant lymphoproliferative disorder, 20 patients (83%) were children aged < 10 years, and 5 patients (21%) died of this disease. Conclusions: Posttransplant lymphoproliferative disorder was the most common malignancy among liver transplant recipients. This disease primarily involved children and was a major cause of morbidity and mortality. Preventive and early diagnostic strategies are justified to decrease morbidity and mortality from de novo malignancy after liver transplant.

show abstract

“…13,14 Gastrointestinal, genitourinary, lung, and oropharyngeal tumors also may develop after liver transplant. In the present study, there were no skin, lung, or oropharyngeal cancers.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Sanaei

Aliakbarian²,

Kazemi³

et al. 2015

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…Our distribution pattern is different from the Western pattern as well as the pattern described from Mediterranean countries. According to the results that have been concluded in the Duke University Medical Center of North Carolina, NMSCs constituted upto 82% of malignancies in organ transplant recipients while PTLD constituted 1-11 % and 6% patients developed Kaposi sarcoma (Zafar et al, 2008). In comparison to this, the results from a study conducted at the Baskent University, Turkey, the most common malignancy was Kaposi sarcoma, found in 32.2%, followed by lymphomas, in 27.1%, and skin cancers in 22% (Yilderim et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Posttransplant Malignancies in Renal Transplant Recipients: 22-years Experience from a Single Center in Pakistan

Yunus

Aziz²,

Mubarak³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To study the incidence, types and distribution pattern of malignant tumors in renal transplant recipients at a single center in Pakistan. Materials and methods: This retrospective study was conducted at Sindh Institute of Urology and Transplantation (SIUT) and included all transplant patients on regular follow-up from November 1986 to December 2008. The original biopsy reports and case files of all patients who developed posttransplant malignancies were reviewed and relevant demographic, clinical, radiological, and histopathological data were retrieved and analyzed. SPSS version 10.0 was used for statistical analysis. Results: Over 22 years of study period, 1816 renal transplants were carried out at our center. Among these, 44 patients developed malignancies constituting an overall incidence rate of 2.4%. All patients in this study were males with a mean age of 34.9±9.5 years (range: 9 to 60 years). The most common type of malignancy was lymphoma (27 patients, 61.4%), followed by Kaposi's sarcoma (11 patients, 25%) and skin malignancies (3 patients, 6.8%). One case each of adenocarcinoma of the gallbladder, acute myeloid leukemia (AML), conjunctival carcinoma-in-situ and seminoma were also diagnosed. Conclusion: Posttransplant malignancies occurring in our renal transplant recipients show different incidence rates and patterns as compared with western studies.

show abstract

“…Most of these patients are pediatric transplant recipients who are seronegative for EBV at the time of the transplant (Zafar et al, 2008). The majority of PTLD cases associated with these children occur within 6 months of the start of a primary EBV infection (Tran et al, 2008).…”

Section: Primary Immunodeficiencymentioning

confidence: 99%

“…However, some of the side-effects of immunosuppressive therapy may lead to an increased prevalence of neoplasia or post-transplant lymphoproliferative disorder (PTLD). PTLD can be a concern after hematopoietic stem cell or solid organ transplant (SOT) and can lead to a variety of lymphoid cancers (Crespo-Leiro et al, 2008;Knowles, 1999;Zafar et al, 2008). PTLD occurs in the presence of immunosuppression, and may be associated with re-activation of EBV or KSHV from latency (Rezk & Weiss, 2007;Schwartz, 2001;Zafar et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…PTLD can be a concern after hematopoietic stem cell or solid organ transplant (SOT) and can lead to a variety of lymphoid cancers (Crespo-Leiro et al, 2008;Knowles, 1999;Zafar et al, 2008). PTLD occurs in the presence of immunosuppression, and may be associated with re-activation of EBV or KSHV from latency (Rezk & Weiss, 2007;Schwartz, 2001;Zafar et al, 2008). EBV À individuals or those with primary or secondary immunodeficiencies are at greatest risk for PTLD (Gottschalk et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation